<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779285</url>
  </required_header>
  <id_info>
    <org_study_id>P04057</org_study_id>
    <secondary_id>EUDRACT NO. 2004-001177-25</secondary_id>
    <nct_id>NCT00779285</nct_id>
  </id_info>
  <brief_title>Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)</brief_title>
  <official_title>Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with&#xD;
      metastatic breast cancer who have previously received chemotherapy with anthracyclines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Events</measure>
    <time_frame>Every 4 weeks during 6 cycles.</time_frame>
    <description>A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of &gt;=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of &gt;=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <description>Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.</description>
    <arm_group_label>Single-arm</arm_group_label>
    <other_name>SCH 200746</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with histologically or cytologically confirmed metastatic breast cancer (no&#xD;
             prior chemotherapy for metastatic disease).&#xD;
&#xD;
          -  Prior treatment with an anthracyclin-containing regimen in the adjuvant setting&#xD;
             (cumulative dose &gt;240mg/m^2 and &lt;360mg/m^2 doxorubicin or &gt;430mg/m^2 and &lt;650mg/m^2&#xD;
             epirubicin).&#xD;
&#xD;
          -  Women &gt;18 years of age.&#xD;
&#xD;
          -  Documented measurable and/or evaluable metastatic breast cancer by appropriate&#xD;
             radiological imaging (computed tomography (CT) scan and/or magnetic resonance imaging&#xD;
             (MRI)).&#xD;
&#xD;
          -  Performance status of at least 60% (Karnofsky index) and a life expectancy of at least&#xD;
             12 weeks.&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;50%.&#xD;
&#xD;
          -  Normal organ function, except if abnormal due to tumor involvement.&#xD;
&#xD;
               -  Adequate bone marrow function as indicated:&#xD;
&#xD;
                    -  Platelets &gt;100,000/mm^3&#xD;
&#xD;
                    -  Hemoglobin &gt;9 g/dL&#xD;
&#xD;
                    -  Neutrophils &gt;1,500/mm^3&#xD;
&#xD;
               -  Adequate renal function as indicated by:&#xD;
&#xD;
                    -  Serum Creatinine &lt;1.5 x the upper limit of normal&#xD;
&#xD;
               -  Adequate liver function, as indicated by:&#xD;
&#xD;
                    -  Bilirubin and aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
                       (ALT) &lt;2 times upper limit of normal (&lt;4 times upper limit of normal when&#xD;
                       related to primary disease)&#xD;
&#xD;
          -  Subjects must be capable to demonstrate their willingness to participate in the study&#xD;
             and comply with its procedures by signing a written informed consent.&#xD;
&#xD;
          -  Women of childbearing potential (includes women who are less than 1 year&#xD;
             postmenopausal and women who become sexually active) must be using an acceptable&#xD;
             method of birth control (e.g., hormonal contraceptive, medically prescribed&#xD;
             intrauterine device (IUD), condom in combination with spermicide) or be surgically&#xD;
             sterilized (e.g., hysterectomy or tubal ligation).&#xD;
&#xD;
          -  Subjects must understand and be able to adhere to the dosing and visit schedules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or is breastfeeding.&#xD;
&#xD;
          -  Patients with moderate or severe heart failure (New York Heart Association (NYHA)&#xD;
             class III/IV).&#xD;
&#xD;
          -  Hypersensitivity to anthracycline therapy or a history of severe hypersensitivity&#xD;
             reactions to products containing CremophorÂ® EL (e.g., cyclosporin for injection&#xD;
             concentrate and teniposide for injection concentrate).&#xD;
&#xD;
          -  Prior chemotherapy for metastatic disease.&#xD;
&#xD;
          -  Clinically significant hepatic disease (except liver metastases of primary disease).&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infection.&#xD;
&#xD;
          -  Radiotherapy in the last 4 weeks or prior radiation therapy to more than one-third of&#xD;
             the hemopoietic sites.&#xD;
&#xD;
          -  Any other currently known malignancy or pre-malignant lesions or any history of other&#xD;
             malignancy within the past five years (except non-melanoma skin cancer and surgically&#xD;
             cured cervical cancer).&#xD;
&#xD;
          -  Symptomatic brain metastasis.&#xD;
&#xD;
          -  Patients who are incapacitated, largely or wholly bedridden or confined to a&#xD;
             wheelchair, and who have little or no ability for self-care.&#xD;
&#xD;
          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,&#xD;
             hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease.&#xD;
&#xD;
          -  Documented human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Any condition (medical, social, psychological) which would prevent adequate follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>February 11, 2010</results_first_submitted>
  <results_first_submitted_qc>February 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2010</results_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Caelyx</title>
          <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caelyx</title>
          <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Events</title>
        <description>A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of &gt;=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of &gt;=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).</description>
        <time_frame>Every 4 weeks during 6 cycles.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caelyx</title>
            <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Events</title>
          <description>A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of &gt;=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of &gt;=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).</description>
          <units>Cardiac Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Caelyx</title>
          <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapulosus exanthema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigator agrees not to publish/publicly present any&#xD;
interim results without prior Sponsor written consent and agrees to provide 30 days written notice prior to submission to permit review of abstracts/manuscripts which report any results. Sponsor has the right to review/comment/edit to ensure confidentiality, information accuracy, and that the presentation is fairly balanced. If the parties disagree, the investigator agrees to meet with Sponsor to discuss/resolve any disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

